MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-17-2025
AIM ImmunoTech Net Income 2011-2026 | AIM
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income AIM ImmunoTech
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.4 M | -19.1 M | -14.4 M | -9.53 M | -9.81 M | -8.26 M | -7.5 M | -15.2 M | -17.4 M | -16.2 M | -17.4 M | -9.02 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.5 M | -19.4 M | -13.6 M |
Quarterly Net Income AIM ImmunoTech
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.28 M | -2.79 M | -3.7 M | - | -3.7 M | -1.84 M | -5.82 M | - | -7.82 M | -4.91 M | -3.66 M | - | -6.38 M | -4.85 M | -3.82 M | - | -3.83 M | -5.88 M | -3.58 M | - | -3.31 M | -3.37 M | -3.81 M | - | -2.95 M | -2.04 M | -3.36 M | - | -3.08 M | -2.42 M | -2.71 M | - | -1.25 M | -2.19 M | -2.82 M | - | -2.86 M | -1.3 M | -2.16 M | - | -3.8 M | -4.84 M | -3.44 M | - | -4.2 M | -4.96 M | -3.84 M | -3.2 M | -5.14 M | -4.28 M | -3.61 M | -5.46 M | -6.59 M | -3 M | -2.31 M | -3.12 M | -2.74 M | -2.29 M | -866 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -866 K | -7.82 M | -3.61 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
NextCure
NXTC
|
-55.8 M | $ 12.67 | 0.52 % | $ 354 M |  USA |
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Liquidia Corporation
LQDA
|
-68.9 M | $ 34.25 | -0.38 % | $ 2.23 B | USA |
 |
Shattuck Labs
STTK
|
-48.8 M | $ 5.02 | 6.13 % | $ 214 M | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
AbCellera Biologics
ABCL
|
-146 M | $ 3.58 | -1.38 % | $ 1.07 B |  Canada |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
ADMA Biologics
ADMA
|
147 M | $ 15.57 | -5.89 % | $ 3.71 B | USA |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Aptorum Group Limited
APM
|
-4.27 M | $ 0.82 | -0.73 % | $ 4.47 M | China |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Anika Therapeutics
ANIK
|
-82.7 M | $ 14.19 | -1.18 % | $ 208 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
-18.5 M | $ 75.6 | -1.22 % | $ 1.46 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
22.4 M | $ 20.24 | 1.91 % | $ 2.55 B | USA |
 |
Applied Therapeutics
APLT
|
-120 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Athersys
ATHX
|
-87 M | - | 3.77 % | $ 22.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-221 M | $ 1.5 | -8.28 % | $ 383 M | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-53.3 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-183 M | $ 159.87 | -2.57 % | $ 7.95 B | USA |
 |
BridgeBio Pharma
BBIO
|
-733 M | $ 65.73 | -1.22 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-11.6 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
-19.8 M | - | -74.18 % | $ 955 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-25 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | Canada |
 |
BioLineRx Ltd.
BLRX
|
-27.1 M | $ 2.72 | -3.31 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
349 M | $ 60.54 | 0.18 % | $ 11.6 B | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 8.26 | -1.31 % | $ 1.36 B | Britain |
 |
CymaBay Therapeutics
CBAY
|
-105 M | - | - | $ 3.45 B | USA |
 |
Codexis
CDXS
|
-65.3 M | $ 1.25 | 16.2 % | $ 91.8 M | USA |
 |
Cabaletta Bio
CABA
|
-67.7 M | $ 3.2 | -6.71 % | $ 3.74 M | USA |